74.59
price up icon0.87%   0.64
pre-market  プレマーケット:  74.20   -0.39   -0.52%
loading
前日終値:
$73.95
開ける:
$73.33
24時間の取引高:
3.51M
Relative Volume:
0.74
時価総額:
$231.33B
収益:
$56.50B
当期純損益:
$8.30B
株価収益率:
28.09
EPS:
2.655
ネットキャッシュフロー:
$8.18B
1週間 パフォーマンス:
+3.84%
1か月 パフォーマンス:
+7.40%
6か月 パフォーマンス:
+8.16%
1年 パフォーマンス:
-8.83%
1日の値動き範囲:
Value
$73.22
$74.60
1週間の範囲:
Value
$72.57
$76.73
52週間の値動き範囲:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
名前
Astrazeneca PLC
Name
セクター
Healthcare (1161)
Name
電話
44 20 3749 5000
Name
住所
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
職員
61,100
Name
Twitter
@AstraZeneca
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
AZN's Discussions on Twitter

AZN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
74.59 229.28B 56.50B 8.30B 8.18B 2.655

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 開始されました Exane BNP Paribas Outperform
2025-02-13 アップグレード UBS Neutral → Buy
2025-02-12 開始されました Morgan Stanley Overweight
2024-11-20 アップグレード UBS Sell → Neutral
2024-11-06 アップグレード Deutsche Bank Sell → Hold
2024-09-13 ダウングレード Deutsche Bank Hold → Sell
2024-05-30 開始されました Goldman Buy
2024-04-16 アップグレード Deutsche Bank Sell → Hold
2024-02-08 ダウングレード Deutsche Bank Hold → Sell
2024-01-23 開始されました Morgan Stanley Overweight
2024-01-16 再開されました UBS Sell
2024-01-03 ダウングレード Jefferies Buy → Hold
2023-12-18 開始されました HSBC Securities Buy
2023-09-25 アップグレード Jefferies Hold → Buy
2023-07-14 開始されました HSBC Securities Buy
2023-07-12 アップグレード UBS Neutral → Buy
2023-07-05 ダウングレード Deutsche Bank Buy → Hold
2023-04-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-01-05 開始されました BMO Capital Markets Outperform
2022-09-15 ダウングレード Credit Suisse Outperform → Neutral
2022-09-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-08-29 アップグレード Argus Hold → Buy
2022-06-14 ダウングレード UBS Buy → Neutral
2022-02-11 アップグレード DZ Bank Sell → Hold
2021-12-07 ダウングレード Jefferies Buy → Hold
2021-08-12 再開されました JP Morgan Overweight
2021-04-12 ダウングレード Argus Buy → Hold
2021-03-16 アップグレード Jefferies Hold → Buy
2021-02-25 アップグレード UBS Neutral → Buy
2021-01-15 開始されました Deutsche Bank Buy
2020-12-07 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-11-30 アップグレード UBS Sell → Neutral
2020-11-11 アップグレード HSBC Securities Reduce → Hold
2020-09-29 開始されました Berenberg Buy
2019-11-22 開始されました SVB Leerink Outperform
2019-10-25 アップグレード Liberum Hold → Buy
2019-04-02 ダウングレード UBS Neutral → Sell
2019-02-05 開始されました Exane BNP Paribas Outperform
2019-01-25 アップグレード Shore Capital Hold → Buy
2018-12-11 再開されました Jefferies Hold
2018-10-09 開始されました Guggenheim Buy
2018-08-16 ダウングレード Jefferies Buy → Hold
2018-03-19 アップグレード Jefferies Hold → Buy
2018-02-06 繰り返されました Leerink Partners Mkt Perform
2018-02-05 繰り返されました Bernstein Outperform
2018-01-18 繰り返されました Leerink Partners Mkt Perform
2017-12-29 アップグレード JP Morgan Neutral → Overweight
2017-10-16 アップグレード Credit Suisse Neutral → Outperform
2017-09-25 アップグレード Exane BNP Paribas Neutral → Outperform
2017-09-22 アップグレード Bernstein Mkt Perform → Outperform
すべてを表示

Astrazeneca PLC (AZN) 最新ニュース

pulisher
Aug 04, 2025

AstraZeneca’s Phase II Study on AZD0901: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

AstraZeneca’s Promising Study on AZD9829 for Blood Cancers: Key Insights for Investors - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

AstraZeneca’s Olaparib Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

AstraZeneca’s New Study on HER2 Expression in Gynecological Cancers: What Investors Need to Know - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging - insights.citeline.com

Aug 04, 2025
pulisher
Aug 04, 2025

AstraZeneca’s Latest Study on Asthma Inhalers: Key Insights for Investors - TipRanks

Aug 04, 2025
pulisher
Aug 03, 2025

What are AstraZeneca PLC Depositary Receipt company’s key revenue driversMassive stock growth - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is AstraZeneca PLC Depositary Receipt company’s balance sheetGet timely advice on market trends - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in AstraZeneca PLC Depositary Receipt stockOutstanding yields - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 02, 2025

AstraZeneca’s AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension - The Globe and Mail

Aug 02, 2025
pulisher
Aug 02, 2025

TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Aug 02, 2025
pulisher
Aug 02, 2025

Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more - Proactive financial news

Aug 02, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments? - Smartkarma

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca Can't Take Diabetes Drug IP Appeal To Top Court - Law360

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s New Study on Endometrial Cancer Treatment: Key Insights for Investors - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s AZD5004: A New Hope for Obesity and Overweight Management - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Ongoing Study on New Breast Cancer Treatment Shows Promise - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s PRIMROSE Study: A New Frontier in Cancer Treatment - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s New Heart Failure Study: Potential Market Impact - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Promising Study on Advanced Cancer Treatments: A Market Overview - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Ongoing Study on Olaparib: Potential Market Implications - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s LYNPARZA Study: Monitoring Safety in Breast Cancer Treatment - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Calquence Study: Ensuring Safety in Real-World Use - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s New COPD Study: Potential Market Impact - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Phase 3b Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Breast Cancer Treatment - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Promising Phase III Study in Metastatic Breast Cancer: What Investors Need to Know - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Latest Phase IIIB Study: A Potential Game-Changer in Advanced Breast Cancer Treatment - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Health - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Latest Study on AZD5004: Implications for Liver Impairment Treatment - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca’s Tezepelumab Study: Real-World Impact on Asthma and Cough - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results? - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

AstraZeneca Announces Updated Share Capital and Voting Rights - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - Yahoo Finance

Aug 01, 2025
pulisher
Jul 31, 2025

AstraZeneca’s GEMINI-NSCLC Study: A New Era in Lung Cancer Research - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AstraZeneca’s eVOLVE-Cervical Study: A New Hope for High-Risk Cervical Cancer - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AstraZeneca’s PHRASE-HF Study: A Game Changer in Heart Failure Treatment? - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AstraZeneca’s Innovative Propellant Study: Market Implications and Future Prospects - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AstraZeneca’s COPD Study: New Propellant Shows Promise - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AstraZeneca’s GEMINI-PeriOp GC Study: A New Horizon in Cancer Treatment - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 31, 2025
pulisher
Jul 30, 2025

Why AstraZeneca Stock Was Topping the Market on Tuesday - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana - Yahoo.co

Jul 30, 2025
pulisher
Jul 30, 2025

FIVE at FIVE: BAE, Taylor Wimpey, Arkle, Cornish Metal, AstraZeneca - Proactive financial news

Jul 30, 2025
pulisher
Jul 30, 2025

AstraZeneca’s Asthma Study Completion: Market Implications and Insights - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

AstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

AstraZeneca’s Promising Phase IIb Study on AZD3427: Market Implications - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

AstraZeneca gets clean bill of health from leading investment bank - Proactive Investors

Jul 30, 2025
pulisher
Jul 30, 2025

AstraZeneca Just Missed Estimates, but Here’s Why Bulls Aren’t Worried Yet - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

Could Astrazeneca completely switch its allegiance to the US? - Yahoo.co

Jul 30, 2025

Astrazeneca PLC (AZN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
大文字化:     |  ボリューム (24 時間):